Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VICTOR ANKOMA-SEY

NPI
1144226515
CMS profile
142864
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$43,350.98

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VICTOR ANKOMA-SEY

NPI 1144226515 · CMS profile ID 142864

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144226515?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144226515?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144226515?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VICTOR ANKOMA-SEY, NPI 1144226515, CMS profile ID 142864, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1144226515?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $43,350.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $49.9909/21/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044600431 CMS
AbbVie Inc. $23.1109/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151397 CMS
AbbVie Inc. $18.7709/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151395 CMS
Gilead Sciences, Inc. $22.7509/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025716189 CMS
INTERCEPT PHARMACEUTICALS, INC. $15.7709/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837707 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.3008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057184093 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.0008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057377609 CMS
AbbVie Inc. $7.4708/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151393 CMS
AbbVie Inc. $15.7808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151391 CMS
Gilead Sciences, Inc. $28.5808/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025576099 CMS
INTERCEPT PHARMACEUTICALS, INC. $12.9808/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837711 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.8708/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057263433 CMS
Mallinckrodt Hospital Products Inc. $30.5907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042807299 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.4107/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057278305 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $111.5007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057277871 CMS
AbbVie Inc. $12.1907/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151389 CMS
INTERCEPT PHARMACEUTICALS, INC. $12.9807/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837703 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.2807/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057125465 CMS
Gilead Sciences, Inc. $26.3407/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025599087 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.8107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057231641 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.2807/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057364715 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.4007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057371659 CMS
Evoke Pharma, Inc. $18.0207/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056625775 CMS
INTERCEPT PHARMACEUTICALS, INC. $10.8607/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837699 CMS
AbbVie Inc. $21.6606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151387 CMS
AbbVie Inc. $2,500.0006/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151385 CMS
AbbVie Inc. $23.7406/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151383 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.8806/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057215849 CMS
Gilead Sciences, Inc. $30.5906/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025560825 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.5806/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057287871 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.8806/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057296759 CMS
AbbVie Inc. $101.1506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151381 CMS
INTERCEPT PHARMACEUTICALS, INC. $11.3505/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837695 CMS
Ipsen Biopharmaceuticals, Inc $27.7705/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045407801 CMS
Gilead Sciences, Inc. $25.7505/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025612077 CMS
INTERCEPT PHARMACEUTICALS, INC. $3,240.0005/17/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837715 CMS
INTERCEPT PHARMACEUTICALS, INC. $105.8605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837719 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.9105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057485471 CMS
INTERCEPT PHARMACEUTICALS, INC. $90.1805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837723 CMS
INTERCEPT PHARMACEUTICALS, INC. $3,240.0005/10/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053837727 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.9705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057242941 CMS
AbbVie Inc. $16.0304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151377 CMS
AbbVie Inc. $15.5704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151379 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.0604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057089571 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.1904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057099339 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.2604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057106801 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.8604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057265047 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.0704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057342229 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2404/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057378097 CMS
AbbVie Inc. $21.1404/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996151375 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,372.47 187
PY2020 $21,123.45 147
PY2021 $34,007.36 148
PY2022 $44,659.13 146
PY2023 $43,350.98 142
PY2024 $53,367.74 163
PY2025 $82,492.56 205

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $47,283.00 21
PY2024 Principal investigator $256,924.43 34
PY2023 Principal investigator $97,952.66 17
PY2022 Recipient $5,726.28 1
PY2022 Principal investigator $33,281.54 10
PY2021 Principal investigator $14,400.32 10
PY2020 Principal investigator $90,343.86 25
PY2019 Principal investigator $52,122.40 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $120.24 10/30/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252234
Principal investigator 1 Ipsen Bioscience Inc. $7,044.77 10/03/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545435
Principal investigator 1 Madrigal Pharmaceuticals $1,594.08 10/03/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248251035
Principal investigator 1 Bausch Health US, LLC $1,239.30 09/17/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842494
Principal investigator 1 Bausch Health US, LLC $1,451.93 08/14/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842490
Principal investigator 1 Madrigal Pharmaceuticals $1,594.08 07/10/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246826
Principal investigator 1 Bausch Health US, LLC $1,513.89 06/11/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842513
Principal investigator 1 Ipsen Bioscience Inc. $2.01 06/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545433
Principal investigator 1 GlaxoSmithKline, LLC. $11,739.63 05/27/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165682
Principal investigator 1 Bausch Health US, LLC $425.25 05/13/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842505
Principal investigator 1 Ipsen Bioscience Inc. $6.70 05/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545431
Principal investigator 1 Madrigal Pharmaceuticals $10,216.94 04/15/2025 Non-covered Recipient Entity
LIVER ASSOCIATES OF TEXAS PA
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242361
Principal investigator 1 Bausch Health US, LLC $1,453.14 04/07/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842509
Principal investigator 1 Ipsen Bioscience Inc. $6.70 04/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545429
Principal investigator 1 Bausch Health US, LLC $1,931.85 03/11/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842498
Principal investigator 1 Ipsen Bioscience Inc. $6.70 03/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545427
Principal investigator 1 Ipsen Bioscience Inc. $4,997.90 02/06/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545423
Principal investigator 1 Ipsen Bioscience Inc. $6.70 02/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545425
Principal investigator 1 Bausch Health US, LLC $425.25 01/13/2025 Non-covered Recipient Entity
Liver Associates of Texas, PA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224842502
Principal investigator 1 Ipsen Bioscience Inc. $1,499.24 01/09/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545421
Principal investigator 1 Ipsen Bioscience Inc. $6.70 01/01/2025 Non-covered Recipient Entity
Liver Associates Of Texas, Pa
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545419